Files
Abstract
Chronic inflammation may contribute to prostate cancer development and progression, with elevated interleukin‑6 (IL‑6) and C‑reactive protein (CRP) associated with poorer outcomes. Omega‑3 (n‑3) fatty acids, known for anti‑inflammatory effects, may reduce prostate cancer risk by lowering these markers. This secondary analysis examined relationships among inflammation, prostate cancer status, and n‑3 fatty acid levels using data from a case‑control study. Plasma IL‑6 and CRP were measured in prostate cancer cases (n=121) and biopsy‑negative controls (n=240), and erythrocyte EPA and DHA were quantified via gas chromatography–mass spectrometry. This study aimed to evaluate inflammatory profiles and the potential modifying role of n‑3 fatty acids in prostate cancer.